TMLB-G9

TMLB-G9 is an orally active B3GAT3 inhibitor (human Kd = 0.72 μM). TMLB-G9 blocks glycosaminoglycan biosynthesis and inhibits chondroitin sulfate biosynthesis in hepatocellular carcinoma cells. TMLB-G9 induces apoptosis by upregulating cleaved PARP and cleaved caspase-3. TMLB-G9 induces G0/G1 cell cycle arrest by upregulating Rb and downregulating CDK1, CDK2, Cyclin A2, Cyclin E1, and phosphorylated Rb. TMLB-G9 inhibits migration and invasion by reversing epithelial-mesenchymal transition, manifested as upregulation of E-cadherin and downregulation of N-cadherin, vimentin, MMP-2, MMP-9, and ZEB1. TMLB-G9 inhibits colony formation. TMLB-G9 exhibits broad-spectrum antitumor activity against multiple cancer cell lines. TMLB-G9 can be used for research on hepatocellular carcinoma.

For research use only. We do not sell to patients.

  • CAS No.: 3127781-85-2
  • Formula: C33H26N4O7
  • Molecular Weight:590.58
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00